Intravitreal (IVT) Injectable Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

Description

Persistence Market Research has conducted a thorough analysis of the Intravitreal (IVT) Injectable Market, providing a comprehensive report detailing its global landscape. This in-depth publication offers valuable insights into the market's dynamics, trends, opportunities, and challenges, providing a comprehensive overview of its structure. Backed by exclusive data and statistics, the research predicts the anticipated growth trajectory of the Intravitreal (IVT) Injectable Market spanning from 2024 to 2031.

Intravitreal injections offer a safe and effective treatment for retinal diseases like diabetic retinopathy and macular degeneration. The global market for these injections is expected to reach $21613.04 million by 2031, with a strong CAGR of 4.9%.

Key Insights:

Intravitreal (IVT) Injectable Market Size (2024): US$19641.06 Mn
Projected Market Value (2031): US$ 21613.04 Mn
Global Market Growth Rate (CAGR 2024 - 2031): 4.9%

Intravitreal (IVT) Injectable Market - Report Scope

The scope of the Intravitreal (IVT) Injectable Market report encompasses a comprehensive analysis of various factors shaping the industry landscape. This includes segmentation based on product types, application areas, end-user industries, and geographical regions. The report covers market size, historical trends, current market dynamics, and future growth prospects within the specified timeframe. Additionally, it examines key market drivers, challenges, opportunities, and regulatory factors influencing market growth. Competitive landscape analysis, including profiles of major players, market share analysis, and strategic initiatives, is also included.

Furthermore, the report provides insights into emerging trends, technological advancements, and investment opportunities in the Intravitreal (IVT) Injectable Market. Overall, the report aims to provide stakeholders with valuable insights to make informed decisions and capitalize on opportunities in the global Intravitreal (IVT) Injectable Market.

Market Growth Drivers

The growth of the Intravitreal (IVT) Injectable Market is driven by several key factors. Firstly, the increasing prevalence of age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseases is driving the demand for intravitreal injectable therapies as effective treatment options. Additionally, advancements in drug delivery technologies and the development of novel therapeutic agents have expanded the treatment options available for intravitreal injections, further fueling market growth. Furthermore, the growing elderly population, particularly in developed regions, is contributing to the rising incidence of retinal diseases, thereby boosting the demand for intravitreal injectable treatments.

Moreover, the expanding indications for intravitreal injections beyond AMD and diabetic retinopathy, such as macular edema, retinal vein occlusion, and uveitis, are widening the market opportunities for intravitreal injectable manufacturers. Additionally, the increasing adoption of intravitreal injections as first-line treatments for certain retinal conditions, owing to their efficacy and minimally invasive nature, is driving market growth. Furthermore, the growing awareness about the importance of early detection and treatment of retinal diseases among both patients and healthcare professionals is expected to further drive market expansion in the coming years.

Market Restraints

Despite its promising growth prospects, the Intravitreal (IVT) Injectable Market faces certain restraints that may hinder its expansion. One significant challenge is the high cost associated with intravitreal injections and related treatment regimens, which can limit patient access to therapy, particularly in regions with limited healthcare resources. Additionally, reimbursement challenges and pricing pressures from payers may impact market growth by affecting the affordability and accessibility of intravitreal injectable treatments for patients.

Moreover, safety concerns related to intravitreal injections, such as the risk of ocular complications like retinal detachment, endophthalmitis, and intraocular pressure elevation, may deter patients and healthcare providers from opting for these treatments. Furthermore, the requirement for frequent injections and the potential for treatment burden, including the need for regular monitoring and follow-up visits, may affect patient compliance and adherence to therapy, thereby impacting market growth. Additionally, the COVID-19 pandemic has disrupted healthcare systems and patient access to elective procedures, leading to a temporary slowdown in market growth.

Opportunities

The Intravitreal (IVT) Injectable Market presents several opportunities for growth and innovation. Firstly, the increasing adoption of intravitreal injections as a standard of care for various retinal diseases presents a significant opportunity for manufacturers to develop targeted therapies with improved efficacy and safety profiles. Additionally, advancements in drug delivery technologies, such as sustained-release implants and biodegradable microspheres, offer opportunities to enhance the duration of action and reduce the frequency of injections, thereby improving patient convenience and compliance.

Moreover, the growing emphasis on personalized medicine and precision therapeutics presents opportunities to develop tailored intravitreal injectable treatments based on genetic and molecular biomarkers, thereby optimizing treatment outcomes and minimizing side effects. Furthermore, expanding indications for intravitreal injections in other ophthalmic conditions, such as glaucoma and ocular inflammation, offer avenues for market expansion and diversification. Lastly, collaborations between industry players, academic institutions, and research organizations are expected to drive innovation and accelerate the development of novel intravitreal injectable therapies. Capitalizing on these opportunities will be crucial for companies operating in the Intravitreal (IVT) Injectable Market to maintain a competitive edge and sustain long-term growth.

Key Questions Answered in Report::

What is the current market size of the Intravitreal (IVT) Injectable Market, and what is its projected growth trajectory?
What factors are driving the demand for intravitreal injectable therapies?
What are the major challenges and restraints faced by the Intravitreal (IVT) Injectable Market?
What opportunities exist for growth and innovation within the Intravitreal (IVT) Injectable Market?
Who are the key players in the market, and how is the competitive landscape structured?

Competitive Intelligence and Business Strategy

Competitive intelligence plays a vital role in shaping effective business strategies within the Bone Void Fillers Market. By closely monitoring competitors' actions, such as product launches, pricing strategies, and market expansions, companies can gain valuable insights into market trends and customer preferences. This information enables them to identify competitive advantages and capitalize on market opportunities.

Furthermore, understanding the competitive landscape allows companies to refine their business strategies and differentiate their offerings from competitors. For example, identifying unmet needs or underserved market segments can guide product development efforts and inform targeted marketing campaigns to gain a competitive edge.

Moreover, competitive intelligence helps companies anticipate and respond to market dynamics, such as regulatory changes or technological advancements, proactively. By staying ahead of the curve, companies can adapt their strategies quickly to maintain relevance and drive growth in the face of evolving market conditions.

Key Companies Profiled

Regeneron Pharmaceuticals, Inc.
Bausch & Lomb
Novartis AG
Allergan
Alimera Sciences
ThromboGenics, Inc.
Bristol-Myers Squibb Company

Intravitreal (IVT) Injectable Market Categorization

Intravitreal (IVT) Injectable Market by Indication

Macular Degeneration
Diabetic Retinopathy
Retinal Vein Occlusion
Endophthalmitis
Others

Intravitreal (IVT) Injectable Market by Drug Class

Anti-VEGF
Corticosteroids
Antibiotics
Antivirals
Antifungals

Intravitreal (IVT) Injectable Market by Region

North America
Latin America
Europe
Asia Pacific
Middle East & Africa (MEA)

Product Code: PMRREP25906

1. Executive Summary

1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations

2. Market Introduction

2.1. Market Taxonomy
2.2. Market Definition

3. Key Inclusions and Exclusions

4. Market Opportunity Analysis

4.1. Macro-Economic Factors
4.2. Opportunity Analysis

5. Market Dynamics

5.1. Drivers
- 5.1.1. Supply Side Drivers
- 5.1.2. Demand Side Drivers
5.2. Restraints
5.3. Trends

6. Epidemiology Analysis

7. Reimbursement Guidelines

8. Pipeline Analysis

9. Global Economic Outlook

9.1. Gross Domestic Indication Type by Region & Country, 2006 - 2023
9.2. Global Healthcare Market Indicators

10. Global Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2032, by Drug Class

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) By Drug Class, 2019-2023
- 10.2.1. Anti-VEGF
- 10.2.2. Corticosteroids
- 10.2.3. Antibiotics
- 10.2.4. Antivirals
- 10.2.5. Antifungals
10.3. Market Size (US$ Mn) Forecast By Drug Class, 2024-2032
10.4. Market Attractiveness Analysis By Drug Class

11. Global Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2032, by Indication

11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) By Indication, 2019-2023
- 11.2.1. Diabetic Retinopathy
- 11.2.2. Macular Degeneration
- 11.2.3. Endophthalmitis
- 11.2.4. Retinal Vein Occlusions
- 11.2.5. Others
11.3. Market Size (US$ Mn) Forecast By Indication, 2024-2031
11.4. Market Attractiveness Analysis By Indication

12. Global Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031, by Distributional Channel

12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) By Distributional Channel, 2019-2023
- 12.2.1. Hospital Pharmacies
- 12.2.2. Retail Pharmacies
- 12.2.3. Drug Stores
- 12.2.4. Mail Order Pharmacies
- 12.2.5. Others
12.3. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
12.4. Market Attractiveness Analysis By Distributional Channel

13. Global Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031, by Region

13.1. Introduction
13.2. Historical Market Size (US$ Mn) By Region, 2019-2023
- 13.2.1. North America
- 13.2.2. Latin America
- 13.2.3. Europe
- 13.2.4. South Asia
- 13.2.5. East Asia
- 13.2.6. Oceania
- 13.2.7. Middle East and Africa
- 13.2.8. Emerging Countries
13.3. Market Size (US$ Mn) Forecast By Region, 2024-2031
13.4. Market Attractiveness Analysis By Region

14. North America Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

14.1. Introduction
14.2. Historical Market Size (US$ Mn) and By Country, 2019-2023
- 14.2.1. U.S.
- 14.2.2. Canada
14.3. Market Size (US$ Mn) Forecast By Country, 2024-2031
14.4. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
- 14.4.1. Anti-VEGF
- 14.4.2. Corticosteriods
- 14.4.3. Antibiotics
- 14.4.4. Antivirals
- 14.4.5. Antifungals
14.5. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
14.6. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
- 14.6.1. Diabetic Retinopathy
- 14.6.2. Macular Degeneration
- 14.6.3. Endophthalmitis
- 14.6.4. Retinal Vein Occlusion
- 14.6.5. Others
14.7. Market Size (US$ Mn) Forecast By Indication, 2024-2031
14.8. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
- 14.8.1. Hospital Pharmacies
- 14.8.2. Retail Pharmacies
- 14.8.3. Drug Stores
- 14.8.4. Mail Order Pharmacies
- 14.8.5. Others
14.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
14.10. Market Attractiveness Analysis
- 14.10.1. By Country
- 14.10.2. By Drug Class
- 14.10.3. By Indication
- 14.10.4. By Distributional Channel
14.11. Drivers and Restraints: Impact Analysis

15. Latin America Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

15.1. Introduction
15.2. Historical Market Size (US$ Mn) and Analysis By Country, 2019-2023
- 15.2.1. Brazil
- 15.2.2. Mexico
- 15.2.3. Rest of Latin America
15.3. Market Size (US$ Mn) Forecast By Country, 2024-2031
15.4. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
- 15.4.1. Anti-VEGF
- 15.4.2. Corticosteriods
- 15.4.3. Antibiotics
- 15.4.4. Antivirals
- 15.4.5. Antifungals
15.5. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
15.6. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
- 15.6.1. Diabetic Retinopathy
- 15.6.2. Macular Degeneration
- 15.6.3. Endophthalmitis
- 15.6.4. Retinal Vein Occlusion
- 15.6.5. Others
15.7. Market Size (US$ Mn) Forecast By Indication, 2024-2031
15.8. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
- 15.8.1. Hospital Pharmacies
- 15.8.2. Retail Pharmacies
- 15.8.3. Drug Stores
- 15.8.4. Mail Order Pharmacies
- 15.8.5. Others
15.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
15.10. Market Attractiveness Analysis
- 15.10.1. By Country
- 15.10.2. By Drug Class
- 15.10.3. By Indication
- 15.10.4. By Distributional Channel
15.11. Drivers and Restraints: Impact Analysis

16. Europe Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

16.1. Introduction
16.2. Historical Market Size (US$ Mn) and Analysis By Country, 2019-2023
- 16.2.1. Germany
- 16.2.2. Italy
- 16.2.3. France
- 16.2.4. U.K.
- 16.2.5. Spain
- 16.2.6. BENELUX
- 16.2.7. Russia
- 16.2.8. Rest of Europe
16.3. Market Size (US$ Mn) Forecast By Country, 2024-2031
16.4. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
- 16.4.1. Anti-VEGF
- 16.4.2. Corticosteriods
- 16.4.3. Antibiotics
- 16.4.4. Antivirals
- 16.4.5. Antifungals
16.5. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
16.6. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
- 16.6.1. Diabetic Retinopathy
- 16.6.2. Macular Degeneration
- 16.6.3. Endophthalmitis
- 16.6.4. Retinal Vein Occlusion
- 16.6.5. Others
16.7. Market Size (US$ Mn) Forecast By Indication, 2024-2031
16.8. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
- 16.8.1. Hospital Pharmacies
- 16.8.2. Retail Pharmacies
- 16.8.3. Drug Stores
- 16.8.4. Mail Order Pharmacies
- 16.8.5. Others
16.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
16.10. Market Attractiveness Analysis
- 16.10.1. By Country
- 16.10.2. By Drug Class
- 16.10.3. By Indication
- 16.10.4. By Distributional Channel
16.11. Drivers and Restraints: Impact Analysis

17. South Asia Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

17.1. Introduction
17.2. Historical Market Size (US$ Mn) and Analysis By Country, 2019-2023
- 17.2.1. India
- 17.2.2. Thailand
- 17.2.3. Indonesia
- 17.2.4. Malaysia
- 17.2.5. Rest of South Asia
17.3. Market Size (US$ Mn) Forecast By Country, 2024-2031
17.4. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
- 17.4.1. Anti-VEGF
- 17.4.2. Corticosteriods
- 17.4.3. Antibiotics
- 17.4.4. Antivirals
- 17.4.5. Antifungals
17.5. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
17.6. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
- 17.6.1. Diabetic Retinopathy
- 17.6.2. Macular Degeneration
- 17.6.3. Endophthalmitis
- 17.6.4. Retinal Vein Occlusion
- 17.6.5. Others
17.7. Market Size (US$ Mn) Forecast By Indication, 2024-2031
17.8. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
- 17.8.1. Hospital Pharmacies
- 17.8.2. Retail Pharmacies
- 17.8.3. Drug Stores
- 17.8.4. Mail Order Pharmacies
- 17.8.5. Others
17.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
17.10. Market Attractiveness Analysis
- 17.10.1. By Country
- 17.10.2. By Drug Class
- 17.10.3. By Indication
- 17.10.4. By Distributional Channel
17.11. Drivers and Restraints: Impact Analysis

18. East Asia Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

18.1. Introduction
18.2. Historical Market Size (US$ Mn) and Analysis By Country, 2019-2023
- 18.2.1. China
- 18.2.2. Japan
- 18.2.3. South Korea
18.3. Market Size (US$ Mn) Forecast By Country, 2024-2031
18.4. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
- 18.4.1. Anti-VEGF
- 18.4.2. Corticosteriods
- 18.4.3. Antibiotics
- 18.4.4. Antivirals
- 18.4.5. Antifungals
18.5. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
18.6. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
- 18.6.1. Diabetic Retinopathy
- 18.6.2. Macular Degeneration
- 18.6.3. Endophthalmitis
- 18.6.4. Retinal Vein Occlusion
- 18.6.5. Others
18.7. Market Size (US$ Mn) Forecast By Indication, 2024-2031
18.8. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
- 18.8.1. Hospital Pharmacies
- 18.8.2. Retail Pharmacies
- 18.8.3. Drug Stores
- 18.8.4. Mail Order Pharmacies
- 18.8.5. Others
18.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
18.10. Market Attractiveness Analysis
- 18.10.1. By Country
- 18.10.2. By Drug Class
- 18.10.3. By Indication
- 18.10.4. By Distributional Channel
18.11. Drivers and Restraints: Impact Analysis

19. Oceania Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

19.1. Introduction
19.2. Historical Market Size (US$ Mn) and Analysis By Country, 2019-2023
- 19.2.1. Australia
- 19.2.2. New Zealand
19.3. Market Size (US$ Mn) Forecast By Country, 2024-2031
19.4. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
- 19.4.1. Anti-VEGF
- 19.4.2. Corticosteriods
- 19.4.3. Antibiotics
- 19.4.4. Antivirals
- 19.4.5. Antifungals
19.5. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
19.6. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
- 19.6.1. Diabetic Retinopathy
- 19.6.2. Macular Degeneration
- 19.6.3. Endophthalmitis
- 19.6.4. Retinal Vein Occlusion
- 19.6.5. Others
19.7. Market Size (US$ Mn) Forecast By Indication, 2024-2031
19.8. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
- 19.8.1. Hospital Pharmacies
- 19.8.2. Retail Pharmacies
- 19.8.3. Drug Stores
- 19.8.4. Mail Order Pharmacies
- 19.8.5. Others
19.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
19.10. Market Attractiveness Analysis
- 19.10.1. By Country
- 19.10.2. By Drug Class
- 19.10.3. By Indication
- 19.10.4. By Distributional Channel
19.11. Drivers and Restraints: Impact Analysis

20. Middle East and Africa Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

20.1. Introduction
20.2. Historical Market Size (US$ Mn) and Analysis By Country, 2019-2023
- 20.2.1. GCC Countries
- 20.2.2. Turkey
- 20.2.3. Northern Africa
- 20.2.4. South Africa
- 20.2.5. Rest of Middle East and Africa
20.3. Market Size (US$ Mn) Forecast By Country, 2024-2031
20.4. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
- 20.4.1. Anti-VEGF
- 20.4.2. Corticosteriods
- 20.4.3. Antibiotics
- 20.4.4. Antivirals
- 20.4.5. Antifungals
20.5. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
20.6. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
- 20.6.1. Diabetic Retinopathy
- 20.6.2. Macular Degeneration
- 20.6.3. Endophthalmitis
- 20.6.4. Retinal Vein Occlusion
- 20.6.5. Others
20.7. Market Size (US$ Mn) Forecast By Indication, 2024-2031
20.8. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
- 20.8.1. Hospital Pharmacies
- 20.8.2. Retail Pharmacies
- 20.8.3. Drug Stores
- 20.8.4. Mail Order Pharmacies
- 20.8.5. Others
20.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
20.10. Market Attractiveness Analysis
- 20.10.1. By Country
- 20.10.2. By Drug Class
- 20.10.3. By Indication
- 20.10.4. By Distributional Channel
20.11. Drivers and Restraints: Impact Analysis

21. Emerging Countries Intravitreal (IVT) Injectables Market Analysis 2019-2023 and Forecast 2024-2031

21.1. Introduction
21.2. Global Vs. Country Growth Comparison

22. China Intravitreal Injectables (IVT) Market Analysis 2019-2023 and Forecast 2024-2031

22.1. Introduction
22.2. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
- 22.2.1. Anti-VEGF
- 22.2.2. Corticosteriods
- 22.2.3. Antibiotics
- 22.2.4. Antivirals
- 22.2.5. Antifungals
- 22.2.6. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
22.3. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
- 22.3.1. Diabetic Retinopathy
- 22.3.2. Macular Degeneration
- 22.3.3. Endophthalmitis
- 22.3.4. Retinal Vein Occlusion
- 22.3.5. Others
22.4. Market Size (US$ Mn) Forecast By Indication, 2024-2031
22.5. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
- 22.5.1. Hospital Pharmacies
- 22.5.2. Retail Pharmacies
- 22.5.3. Drug Stores
- 22.5.4. Mail Order Pharmacies
- 22.5.5. Others
22.6. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
22.7. Market Attractiveness Analysis
- 22.7.1. By Country
- 22.7.2. By Drug Class
- 22.7.3. By Indication
- 22.7.4. By Distributional Channel
22.8. PESTLE Analysis
22.9. Drivers and Restraints: Impact Analysis

23. India Intravitreal Injectables (IVT) Market Analysis 2019-2023 and Forecast 2024-2031

23.1. Introduction
23.2. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
- 23.2.1. Anti-VEGF
- 23.2.2. Corticosteriods
- 23.2.3. Antibiotics
- 23.2.4. Antivirals
- 23.2.5. Antifungals
23.3. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
23.4. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
- 23.4.1. Diabetic Retinopathy
- 23.4.2. Macular Degeneration
- 23.4.3. Endophthalmitis
- 23.4.4. Retinal Vein Occlusion
- 23.4.5. Others
23.5. Market Size (US$ Mn) Forecast By Indication, 2024-2031
23.6. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
- 23.6.1. Hospital Pharmacies
- 23.6.2. Retail Pharmacies
- 23.6.3. Drug Stores
- 23.6.4. Mail Order Pharmacies
- 23.6.5. Others
23.7. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
23.8. Market Attractiveness Analysis
- 23.8.1. By Country
- 23.8.2. By Drug Class
- 23.8.3. By Indication
- 23.8.4. By Distributional Channel
23.9. PESTLE Analysis
23.10. Drivers and Restraints: Impact Analysis

24. Mexico Intravitreal Injectables (IVT) Market Analysis 2019-2023 and Forecast 2024-2031

24.1. Introduction
24.2. Historical Market Size (US$ Mn) and Trend Analysis By Drug Class, 2019-2023
- 24.2.1. Anti-VEGF
- 24.2.2. Corticosteriods
- 24.2.3. Antibiotics
- 24.2.4. Antivirals
- 24.2.5. Antifungals
24.3. Market Size (US$ Mn) Forecast By Drug Class, 2024-2031
24.4. Historical Market Size (US$ Mn) and Trend Analysis By Indication, 2019-2023
- 24.4.1. Diabetic Retinopathy
- 24.4.2. Macular Degeneration
- 24.4.3. Endophthalmitis
- 24.4.4. Retinal Vein Occlusion
- 24.4.5. Others
24.5. Market Size (US$ Mn) Forecast By Indication, 2024-2031
24.6. Historical Market Size (US$ Mn) and Trend Analysis By Distributional Channel, 2019-2023
- 24.6.1. Hospital Pharmacies
- 24.6.2. Retail Pharmacies
- 24.6.3. Drug Stores
- 24.6.4. Mail Order Pharmacies
- 24.6.5. Others
24.7. Market Size (US$ Mn) Forecast By Distributional Channel, 2024-2031
24.8. Market Attractiveness Analysis
- 24.8.1. By Country
- 24.8.2. By Drug Class
- 24.8.3. By Indication
- 24.8.4. By Distributional Channel
24.9. PESTLE Analysis
24.10. Drivers and Restraints: Impact Analysis

25. Forecast Factors: Relevance and Impact

26. Forecast Assumptions

27. Competition Analysis

27.1. Competition Dashboard
27.2. Competition Deep Dive
- 27.2.1. F. Hoffmann-La Roche Ltd
  - 27.2.1.1. Overview
  - 27.2.1.2. Key Financials
  - 27.2.1.3. SWOT Analysis
  - 27.2.1.4. Key Developments
  - 27.2.1.5. Key Strategy
- 27.2.2. Regeneron Pharmaceuticals, Inc.
  - 27.2.2.1. Overview
  - 27.2.2.2. Key Financials
  - 27.2.2.3. SWOT Analysis
  - 27.2.2.4. Key Developments
  - 27.2.2.5. Key Strategy
- 27.2.3. Bausch & Lomb
  - 27.2.3.1. Overview
  - 27.2.3.2. Key Financials
  - 27.2.3.3. SWOT Analysis
  - 27.2.3.4. Key Developments
  - 27.2.3.5. Key Strategy
- 27.2.4. Novartis AG
  - 27.2.4.1. Overview
  - 27.2.4.2. Key Financials
  - 27.2.4.3. SWOT Analysis
  - 27.2.4.4. Key Developments
  - 27.2.4.5. Key Strategy
- 27.2.5. Allergan
  - 27.2.5.1. Overview
  - 27.2.5.2. Key Financials
  - 27.2.5.3. SWOT Analysis
  - 27.2.5.4. Key Developments
  - 27.2.5.5. Key Strategy
- 27.2.6. Alimera Sciences
  - 27.2.6.1. Overview
  - 27.2.6.2. Key Financials
  - 27.2.6.3. SWOT Analysis
  - 27.2.6.4. Key Developments
  - 27.2.6.5. Key Strategy
- 27.2.7. ThromboGenics, Inc.
  - 27.2.7.1. Overview
  - 27.2.7.2. Key Financials
  - 27.2.7.3. SWOT Analysis
  - 27.2.7.4. Key Developments
  - 27.2.7.5. Key Strategy
- 27.2.8. Bristol-Myers Squibb Company
  - 27.2.8.1. Overview
  - 27.2.8.2. Key Financials
  - 27.2.8.3. SWOT Analysis
  - 27.2.8.4. Key Developments
  - 27.2.8.5. Key Strategy